The 36-month beta value for ETNB is at 1.00. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ETNB is 99.24M, and currently, shorts hold a 7.00% of that float. The average trading volume for ETNB on September 27, 2024 was 722.95K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ETNB) stock’s latest price update
89bio Inc (NASDAQ: ETNB) has seen a decline in its stock price by -0.81 in relation to its previous close of 7.42. However, the company has experienced a -11.22% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-19 that SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on September 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
ETNB’s Market Performance
89bio Inc (ETNB) has experienced a -11.22% fall in stock performance for the past week, with a -19.47% drop in the past month, and a -2.39% drop in the past quarter. The volatility ratio for the week is 6.14%, and the volatility levels for the past 30 days are at 6.09% for ETNB. The simple moving average for the past 20 days is -12.28% for ETNB’s stock, with a -23.07% simple moving average for the past 200 days.
Analysts’ Opinion of ETNB
Many brokerage firms have already submitted their reports for ETNB stocks, with BofA Securities repeating the rating for ETNB by listing it as a “Buy.” The predicted price for ETNB in the upcoming period, according to BofA Securities is $30 based on the research report published on April 22, 2024 of the current year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see ETNB reach a price target of $15, previously predicting the price at $24. The rating they have provided for ETNB stocks is “Sector Perform” according to the report published on January 12th, 2024.
ETNB Trading at -13.48% from the 50-Day Moving Average
After a stumble in the market that brought ETNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.74% of loss for the given period.
Volatility was left at 6.09%, however, over the last 30 days, the volatility rate increased by 6.14%, as shares sank -18.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.21% lower at present.
During the last 5 trading sessions, ETNB fell by -11.22%, which changed the moving average for the period of 200-days by -25.35% in comparison to the 20-day moving average, which settled at $8.31. In addition, 89bio Inc saw -34.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETNB starting from PALEKAR ROHAN, who sale 52,718 shares at the price of $10.91 back on Apr 01 ’24. After this action, PALEKAR ROHAN now owns 459,171 shares of 89bio Inc, valued at $575,153 using the latest closing price.
RA CAPITAL MANAGEMENT, L.P., the Director of 89bio Inc, purchase 1,350,000 shares at $15.35 during a trade that took place back on Mar 04 ’24, which means that RA CAPITAL MANAGEMENT, L.P. is holding 12,431,584 shares at $20,722,500 based on the most recent closing price.
Stock Fundamentals for ETNB
Current profitability levels for the company are sitting at:
- -817.37 for the present operating margin
- 0.8 for the gross margin
The net margin for 89bio Inc stands at -746.21. The total capital return value is set at -0.35. Equity return is now at value -36.50, with -32.50 for asset returns.
Based on 89bio Inc (ETNB), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.4. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -116.34.
Currently, EBITDA for the company is -150.93 million with net debt to EBITDA at 0.97. When we switch over and look at the enterprise to sales, we see a ratio of 2541.14. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.92.
Conclusion
In conclusion, 89bio Inc (ETNB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
